JAK1 and rheumatoid arthritis: The results for a third drug were presented by Frank Brosius, who reported on baricitinib, a Janus kinase 1/2 (JAK1/2) inhibitor that is currently being tested in Phase 3 clinical trials for rheumatoid arthritis.